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Abstract
Background: CD4
+CD25
+ regulatory T cells (Tregs), a heterogeneous population, were enrichment in tumor mass and
played an important role in modulating anti-tumor immunity. Recently, we reported a Treg subset, CCR6
+ Tregs but not
CCR6
2Tregs, were enriched in tumor mass and closely related to poor prognosis of breast cancer patients. However, the
underlying mechanism remains elusive. Here, we carefully evaluate the enrichment of CCR6
+Tregs in tumor mass during
progression of breast cancer and explore its possible mechanism.
Methodology/Principal Findings: The frequency of CCR6
+Tregs in tumor infiltrating lymphocytes (TILs ) was analyzed at
early stage and at late stage of tumor in a murine breast cancer model by FACS respectively. The expansion of CCR6
+Tregs
and their CCR6
2 counterpart in tumor mass were determined by BrdU incorporation assay. The effect and its possible
mechanism of tumor-resident antigen presenting cells (APCs) on the proliferation of CCR6
+Tregs also were evaluated. The
role of local expansion of CCR6
+Tregs in their enrichment and suppression in vivo also was evaluated in adoptive cell
transfer assay. We found that the prior enrichment of CCR6
+Tregs but not CCR6
2Tregs in tumor mass during progression of
murine breast cancer, which was dependent on the dominant proliferation of CCR6
+ Tregs in situ. Further study
demonstrated that tumor-resident DCs triggered the proliferation of CCR6
+Treg cells in TGF-b dependent manner. Adoptive
transfer of CCR6
+Tregs was found to potently inhibit the function of CD8
+T cells in vivo, which was dependent on their
proliferation and subsequently enrichment in tummor mass.
Conclusions/Significance: Our finding suggested that CCR6
+ Tregs, a distinct subset of Tregs, exert its predominant
suppressive role in tumor immunity through prior in situ expansion, which might ultimately provide helpful thoughts for
the designing of Treg-based immunotherapy for tumor in the future.
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Introduction
CD4
+CD25
+ regulatory T cells (Treg), a subpopulation of
CD4
+ T cells constitutively expressing transcription factor fork-
head box protein3 (Foxp3), consist 5–10% peripheral CD4
+T cells
in normal human and mice [1]. CD4
+CD25
+ Tregs effectively
suppress the proliferation and activity of both CD4
+CD25
2 and
CD8
+ T cells in a contact-dependent manner through inhibition of
interleukin 2 (IL-2) production [2]. Accumulating data have
indicated that Tregs were enriched in tumor mass and potently
inhibited the anti-tumor immunity mediated by CD4
+Th1 and
CD8
+CTL [3,4]. However, the exact mechanism of Tregs were
enriched in tumor mass remains not fully understood.
Recently, some findings have indicated that there are distinct
subsets of Tregs which play different roles in diverse animal
models, mediating immune suppression or immune tolerance
[5–9]. However, whether a distinct subset of Tregs is present in
tumor environment and their role in mediating immunosuppres-
sion remains to be elucidated [10]. Previous study demonstrated a
new subset of Tregs, which express CC chemokine receptor type 6
(CCR6), played an important role in the pathogenesis of
experimental allergic encephalomyelitis (EAE) [11]. Kitamura
et al further found that CCR6
+ regulatory T cells contributed to
the pathogenesis of experimental colitis [12]. In the setting of
tumors, Lamprecht et al reported that CCR6
+Tregs might favor
immune escape of Hodgkin/Reed-Sternberg (HRS) cells [13].
Our recent work further showed that CCR6
+ subset of Treg cells
were dominantly enriched in tumor mass and closely related to
poor prognosis of breast cancer patients [14]. Combing these data
suggested that CCR6
+Tregs might play a critical role in
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e20282immunosuppression of anti-tumor immunity. However, the
underlying mechanism of the enrichment of this Treg subset in
tumor mass remains to be elucidated, which might be helpful for
the understanding of mechanisms of contribution of distinct Treg
subsets to immunosuppression and ultimately aid the designing of
therapy for treating tumor patients.
To this end, in the present study, the distribution of CCR6
+
Tregs was evaluated in a murine breast cancer model. Our data
showed that CCR6
+Tregs were dominantly enriched in the tumor
mass during tumor progression. Notably, we provided evidence
that the predominant proliferation of CCR6
+ Tregs was crucial for
their enrichment and suppressive effects in vivo. Finally, the
possible role of tumor resident DCs in the proliferation of CCR6
+
Tregs was studied.
Results
CCR6
+Foxp3
+ regulatory T cells were enriched in tumor
mass during progression of breast tumor
Our previous data found that CCR6
+Foxp3
+ regulatory T cells
were dominantly enriched in tumor mass and closely related to
poor prognosis of breast cancer patients [14], to further investigate
the mechanism of the enrichment of this tumor-resident Treg
subset, the frequency of CCR6
+ Tregs in TILs during tumor
progression was observed. As shown in fig. 1a, the expression of
CCR6 and Foxp3 were evaluated inside the CD4
+ CD25
neg,
CD4
+ CD25
low and CD4
+ CD25
high gated populations of TILs
from 4T1 bearing mice. We found that CCR6 was preferentially
expressed on CD4
+ CD25
high Foxp3
+ regulatory T cells and
defined a distinct subset of CCR6
+CD4
+ CD25
high Foxp3
+
regulatory T cells in 4T1 bearing mice (Fig. 1a). Next, we
analyzed the phenotype and inhibitory function of CCR6
+Tregs.
The expression level of Foxp3, GITR, CTLA-4, CCR4 and
CCR8 on CCR6
+ Tregs were similar to those on CCR6
2 Tregs
indicating both CCR6
+ and CCR6
2 Tregs displayed regulatory
phenotype (Fig. 1b). And the inhibitory effect of CCR6
+Tregs on
responder CD4
+ CD25
2T cells was comparable to that of CCR6
2
Tregs (Fig. 1c, p.0.05). Of note, CCR6
+ Tregs expressed low
level of CD62L and high level of CD44, displaying an effector/
memory phenotype (Fig. 1b). We further analyzed the frequency
of CCR6
+Tregs and CCR6
2Tregs at day 10 or 28 (defined as
early and late stage respectively) and found that the CCR6
2Treg
frequency in TILs (6.1%) at late stage of tumor was equal to that
(5.9%) at early stage of tumor; while the frequency of
CCR6
+Tregs in TILs (12.5%) at late stage of tumor was
significantly higher than that (5.7%) at early stage of tumor
(Fig. 1d, p,0.05). Moreover, CCR6
+Treg frequency at late stage
of tumor in TILs was higher than that in DLNs; In contrast,
frequency of CCR6
2 Tregs in TILs at late stage was similar to that
in DLNs (Fig. 1d, p.0.05). In addition, there wasn’t any change in
the frequency of CCR6
+Tregs or CCR6
2Tregs in PBMCs during
tumor progression. These data showed that CCR6
+ Tregs, but not
their CCR6
2 counterpart, accumulated in tumor mass during
tumor progression.
Expansion of CCR6
+Tregs contributed to their
accumulation
We next tried to elucidate whether selective enrichment of CCR6
+
Tregs in the tumor mass was related to their preferable recruitment or
their prior in site proliferation. And it was found that CCR6
+Tregs
expressed equal level of CCR4 and CCR8 as that of CCR6
2Tregs
(Fig. 1b) and displayed simlar response to CCL17 and CCL22 to
CCR6
2Tregs did (Fig S1). In addition, the concentration of CCL17,
CCL20 and CCL22 in supernatant also were determined (Fig S2).
However, cultured supernatant of 4T1 tumor cells attracted similar
counts of CCR6
+ and CCR6
2T r e g s( F i gS 3 ) .I ti ss e e m i n g l y
recuitment of CCR6
+Tregs didn’t be mostly responsible for their
dominate enrichment in tumor sites. Previous finding showed that
Tregs could proliferate in tumor mass. Then, we presumed that the
proliferation of CCR6
+Tregs may differ from that of CCR6
2Tregs,
which led to the dominant enrichment of CCR6
+Tregs. It was found
that 52.6% CCR6
+Tregs were BrdU-positive, significantly higher than
13.4% BrdU-positive- CCR6
2Tregs (Fig. 2a, p,0.05) in tumor mass.
Moreover, the percentage of S phage of CCR6
+Tregs was also higher
than that of CCR6
2Tregs (p,0.05). And the proliferation of tumor
infiltrating CCR6
+Tregs was higher than that in DLNs and PBMCs
(data not shown). To further confirm this observation, CCR6
+ or
CCR6
2Tregs were sorted from 4T1 bearing mice and labeled with
CFSE, then injected into tumor mass in 4T1 bearing syngeneic mice
respectively. 10 days later, the proliferation of CCR6
+Treg cells or
CCR6
2Treg cells was analyzed. It was found that the percentage of
CFSE
+ CCR6
+Treg cells (41.64%) were significantly higher than that
of CFSE
+CCR6
2Treg cells (14.21%) (Fig. 2b, p,0.05) indicating that
CCR6
+Tregs could more powerfully proliferate than CCR6
2Tregs in
tumor mass.
To elucidate whether local prior proliferation of CCR6
+Tregs
contributed to their accumulation in tumor mass, we treated 4T1
bearing mice with vinblastine (a cell cycle inhibitor) as described
previously [16]. As expected, vinblastine treatment significantly
reduced the in situ proliferation of CCR6
+Tregs (Fig. 2c, p,0.05)
compared with control group. Importantly, the proportion of
CCR6
+Tregs in tumor mass in vinblastine treated groups also
decreased significantly compared with control group (Fig. 2d,
p,0.05). In contrast, there was little effect of vinblastine treatment
on the proportion of CCR6
2Tregs in tumor mass. Subsequently,
vinblastine treatment also significantly reduced the proportion of
Tregs in tumor mass (Fig. 2e, p,0.05). Of note, CCR4 and CCR8
expression on CCR6
+or CCR6
2Tregswasnotalteredbyvinblastine
(data not shown) and CCL17 or CCL22 could equivalently
chemotract vinblastine pretreated CCR6
+ and CCR6
2Tregs in
vitro (unpublished data). Combining these data suggested that
compared to CCR6
2Tregs, local prior proliferation of CCR6
+
Tregs was critical for their dominant accumulation in tumor mass.
Tumor-resident DCs selectively triggered the
proliferation of CCR6
+Treg
Since the local proliferation was crucial for the in vivo
accumulation of CCR6
+Tregs. Next we tried to find whether
tumor-resident APCs could promote the proliferation of CCR6
+
Tregs. Tumor-resident CD11c
+ DCs, macrophages or B cells were
isolated from tumor mass of 4T1 bearing mice and then cultured
with CCR6
+Tregs or CCR6
2Tregs at 2:1 ratio in vitro. It was
shown that tumor-resident DCs significantly stimulated the
proliferation of CCR6
+ Tregs in vitro in a time and dose dependent
manner (Fig. 3a,b and c, p,0.05), while no such effect was
observed for any of the other APCs isolated from tumor mass
(Fig. 3a, p.0.05). Moreover, there were moderate effect of tumor-
resident DCs on CCR6
2Tregs (Fig. 3a, p.0.05). In addition, DCs
derived form DLNs had little effect on the proliferation of
CCR6
+Tregs (Fig. 3b,c), partially explaining why lower prolifer-
ation of CCR6
+Tregs in DLNs was found than in TILs. Moreover,
the DC-expanded CCR6
+Tregs sustained their expression of
Foxp3 and CCR6 (data not shown) and the suppressive function
(Fig. 3e). Moreover, DCs induced the proliferation of CCR6
+Treg
in MHC-class II-dependent way (Fig. 3d, p,0.05). To further
confirm the effect of DCs on the proliferation of CCR6
+Tregs, we
further intratumoral injected DCs into tumor mass in 4T1 bearing
syngeneic mice and found that DCs could also significantly
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+Foxp3
+ regulatory T cells were enriched in tumor mass during tumor progress. (A) Tumor infiltrating cells (TILs) from 4T1
bearing mice on day 10 or day 28 were stained by anti-CD4, anti-CD25, anti-Foxp3 and anti-CCR6 antibodies and analyzed by Flow cytometry. The
gating strategy and expression of Foxp3 were shown. Dot plots showing examples of CCR6/Foxp3 expression in CD4
+ CD25
neg, CD4
+ CD25
low, and
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+Tregs in tumor mass (Fig. 3e,
p,0.05). Similar to above data, we also find little effect of DCs on
the proliferation of CCR6
2Tregs in vivo (Fig. 3e, p.0.05).
Different from the report that tumor cells could induce the
proliferation of Tregs [17], we couldn’t observe any effect of 4T1
tumor cells on the proliferation of CCR6
+Tregs in vitro (data not
shown).
DC-derived TGF-b was crucial for in situ expansion of
CCR6
+Treg. Previous finding demonstrated TGF-b was critical
for Treg proliferation in vivo [18,19]. Hence, anti-TGF-b
antibody was administered to mice before analyzing the
BrdU
+CCR6
+Tregs. As shown in fig. 4a, anti-TGF-b antibody
treatment significantly reduced the proliferation and frequency of
CCR6
+Tregs in tumor mass, suggesting TGF-b was critical for the
in situ CCR6
+Tregs proliferation. Then, the expression level of
TGF-b in tumor-resident DCs was analyzed. As shown in fig. 4d,
tumor-resident DCs expressed high level of TGF-b. anti-TGF-b
treatment also abrogated nearly 65% in vitro proliferation of
CCR6
+Tregs triggered by DCs (Fig. 4c, p,0.05). To exclude the
influence of CCR6
+Tregs derived TGF-b on the effects of DCs,
we transfected TGF-b RNAi into DCs. As shown in fig. 4d, TGF-
b RNAi could significantly reduce the TGF-b secretion of DCs.
Importantly, the proliferation of CCR6
+Tregs in TGF-b-RNAi
transfected DCs group decreased significantly compared with
control group (Fig. 4e, p,0.05). These data indicated that tumor-
derived CD11c
+DCs triggered the proliferation of CCR6
+Treg in
a TGF-b dependent manner.
In situ expansion of CCR6
+Tregs was crucial for their
enrichment and suppression in vivo
Our recent work indicated that adoptive transfer of
CCR6
+Tregs more effectively suppressed the anti-tumor CD8
+T
cells than their CCR6
2 counterparts did [20]. Then, whether in
situ prior expansion of CCR6
+Tregs might be responsible for their
enrichment and subsequently suppressive effects in vivo was
investigated. As shown in fig. 5a,b, CCR6
+ or CCR6
2Tregs were
sorted from TILs and pretreated with or without vinblastine. Then
cells were transferred into 4T1 bearing syngeneic nude mice with
4T1 specific CD8
+T cells at a ratio of 1:2 respectively. As shown in
fig. 5a, vinblastine pre-treatment obviously decreased CCR6
+Treg
frequency in tumor mass from 5.43% to 2.13% (p,0.05).
Correspondingly, IFN-c production of CD8
+T cells in CCR6
+
Tregs co-transferred mice was 2.89%, while it increased
dramatically to 6.11% when the co-transferred CCR6
+Tregs were
pre-treated with vinblastine (Fig. 5b, p,0.05). Similar results were
obtained on the proliferation, as well as expression of CD107a and
Granzyme B, of CD8
+T cells (Fig. 5c,d, p,0.05). Finally, the size
of tumor mass in CCR6
+Tregs co-transferred mice was signifi-
cantly elevated compared with that in CD8
+T cells transferred
group and CCR6
2Tregs co-transferred group, while it decreased
obviously in vinblastine pre-treated CCR6
+ Tregs co-transferred
group(Fig. 5e, p,0.05).
In addition, vinblastine pretreatment also limitedly reduced the
percentage of CCR6
2Tregs in tumor mass (Fig. 5a, p.0.05) and
led to slightly elevated IFN-c production and proliferation, as well
as the expression of CD107a and Granzyme B, of CD8
+T cells
(Fig. 5b,c,d, p.0.05). Altogether, all our data suggested that in situ
dominant proliferation capacity was critical for the enrichment
and suppressive effect of CCR6
+Tregs in vivo.
Discussion
In the present study, we showed that CCR6
+Tregs but not
CCR6
2Tregs were enriched in tumor mass during tumor
progression in murine breast cancer model. And it was found
that predominant in situ proliferation of CCR6
+Tregs was critical
for their local enrichment and subsequently their suppression in
tumor immunity. Tumor resident DCs were found to trigger the
proliferation of CCR6
+Tregs in a TGF-b dependent manner.
Enrichment of CD4
+CD25
+regulatory T cells in tumor mass
was found in various tumor animal model and clinical tumor
patients [1,4]. Our previous study showed that CCR6
+Treg cells
were dominantly enriched in tumor mass and closely related to
poor prognosis of breast cancer patients [14]. In this study, we
extended our pervious finding by demonstrating that CCR6
+
Tregs, but not CCR6
2 Tregs were enriched in tumor mass during
progression of breast cancer. CCR6
+Tregs displayed a phenotypic
and functional characteristic of memory-effector T cells, express-
ing high level of CD44 and low level of CD62L, which is
consistent with other work [11].
Previous evidence suggested that chemokine family members, such
as CCL17 and CCL22, direct the movement of Tregs in tumor mass
[21,22]. Recent evidence further indicated that conversion of
CD4
+CD25
2 T cells into Tregs, as well as local proliferation of Tregs
also was contributed to local enrichment of Tregs [23,24]. Notably, we
extended others work by demonstrating that CCR6
+ Tregs, but not
CCR6
2Tregs, predominantly proliferate in tumor mass. Our recent
finding suggested that adoptive transfer of CCR6
+ Tregs could more
potently inhibit the function of CD8
+T cells in vivo than CCR6
2Tregs
did. Here, we further provided direct evidence showed that prior
proliferation of CCR6
+ Tregs was critical for their local enrichment
and subsequently contributed to their suppressive effect on anti-tumor
CD8
+T cells in vivo. Then, our data also suggested that the
proliferation of regulatory T cells, as well as conversion of non-
regulatory T cells into Treg cells and migration of Treg, was crucial for
their enrichment and suppressive capacity in tumor mass.
CD11c
+ DCs were found by our previously finding to be
accumulated in tumor sites during tumor progression [25]. Here,
we further found that tumor-resident DCs significantly triggered
the proliferation of CCR6
+T cells in a TGF-b dependent manner.
Similar work also reported immature DCs-induced TGF-b-
dependent Treg proliferation [26,27]. Meanwhile, our data found
that DLN derived DCs had little effect on the proliferation of
CCR6
+Tregs suggesting that distinct DC subsets have heteroge-
neous effects on Tregs which awaits further research works.
To the discrepancies on the proliferation of CCR6
+Tregs and
CCR6
2Tregs in vivo, we presumed that the prior proliferation of
CCR6
+Tregs was dominantly dependent on two factors. On the one
hand, memory T cells are more readily activated than naive cells, as
evidenced by their ability to respond to lower doses of Ag, by their
lesser dependence on co-stimulatory receptor-ligand interactions, and
by their enhanced responses to stimulation with TCR antibody
[28,29]. Our present data showed that CCR6
+Tregs displayed
effector-memory T cells phenotype. Rivino et al reported that CCR6
+
memory T cells secreted cytokine efficiently in response to suboptimal
CD4
+ CD25
high gated populations of TILs from 4T1 bearing mice are reported. (B) FACS analysis of the phenotypes of CCR6
2 regulatory T cells and
CCR6
+ regulatory T cells. Dot lines here represent the isotype control. (C) Suppressive capacity of the sorted CCR6
2 regulatory T cells and CCR6
+
regulatory T cells against CD4
+ CD25
2Teff cells, determined by [
3H]-thymidine incorporation respectively. (D) As gated on fig. 1a, the percentage of
CCR6
2 Foxp3
+ regulatory T cells and CCR6
+ Foxp3
+ regulatory T cells in CD4
+ T cells from peripheral blood mononuclear cells (PBMCs), draining
lymph nodes(DLNs) and TILs were analyzed at day 10 or day 28 (termed as early or late stage) (n=12) by FACS and calculated. *p,0.05.
doi:10.1371/journal.pone.0020282.g001
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Kleinewietfeld et al further reported that CCR6
+Tregs showed more
sensitivity to TCR antibody [11]. On the other hand, the functional
character of tumor-resident APC might also be critical for the different
proliferation of CCR6
+Tregs and CCR6
2Tregs in vivo. It is
demonstrated that tumor-resident DCs expressed low level of MHC
Class-II molecules and co-stimulatory molecules, displayed immature
phenotype [26,31,32]. Moreover, our present data also showed that
tumor-resisent DCs could significantly promote the proliferation of
CCR6
+Tregs but not CCR6
2Tregs. Therefore, the different
proliferation of CCR6
+Tregs and CCR6
2Tregs in tumor mass might
be partly attributed to their different sensitivity following interaction
with intra-tumoral DCs. However, the exact mechanism remains to
be elucidated in successive work.
In all, this research represents as the first report to elucidate
the mechanism of the selective enrichment of CCR6
+Tregs but
not CCR6
2Tregs in tumor mass. And tumor-resident DC
secreting TGF-b seems to be crucial for the in situ expansion
and suppressive effect of CCR6
+Tregs in vivo.T h i ss t u d ym i g h t
throw a new insight on the understanding of orientation and
function-sustaining mechanism of unique regulatory T cell
subset in the setting of breast tumor and provide helpful
thoughts for the designing of Treg-based immunotherapy for
tumor in the future.
Materials and methods
Animals
Female Balb/c mice and Balb/c nude mice 5–6 weeks of age
were purchased from the Center of Experimental Animal, Fudan
University (Shanghai, China). All animals were housed in the
pathogen free mouse colony at our institution and all animal
experiments were performed according to the guidelines for the
Care and Use of Laboratory Animals (Ministry of Health, PR
China, 1998) and all the experimental procedure was approved by
the ‘‘the ethical guidelines of Shanghai Medical Laboratory
Animal Care and Use Committee’’ (permit number:2007013).
Cell lines
4T1 cell line, a Balb/c spontaneous metastatic mammary
carcinoma, were cultured at 37uC under 5% CO2 in completed
RPMI 1640 (GIBICO, Grand land, NY, USA) medium
containing 10% heat-inactivated fetal bovine serum and supple-
mented with 2 mM glutamine, 100 IU/ml penicillin, and 100 ug/
ml streptomycin sulfate.
Nude mice tumor model and co-transfer experiment
Syngeneic female nude mice were injected subcutaneously
with 0.2 ml of a single-cell suspension containing 2610
5 4T1
adenocarcinoma cells in the right anterior mammary fat pad
region. 7 days later, 4T1 specific CD8
+T cells were transferred
with or without CCR6
+Tregs and CCR6
2Tregs at a ratio of 2:1
through tail vein respectively. 21 days later, the size of tumor mass
in each group was obtained as previous described [3]. To obtain
4T1 specific CD8
+T cells, Balb/c mice were immunized with
inactivated 4T1 tumor cells 3 times, with 1-week-interval. Then
CD8
+ T cells were sorted from splenocytes and re-stimulated with
inactivated 4T1 tumor cells for 24 h in vitro.
Isolation of TILs
The lymphocytes were harvested from 4T1 tumors by a
discontinuous density gradient method. Briefly, 4T1 tumors were
removed aseptically and minced with scissors into 1–2 mm
3
pieces. The minced tumors were then stirred in 40 ml complete
RPMI 1640 containing 40 mg collagenase, type IV(Sigma), 4 mg
deoxyribonuclease (Sigma) and 100 U hyaluronidase (Sigma) for
3 h at room temperature. The tumor cell suspension was filtered
through a nylon-mesh screen with pores of 50 mm to remove cell
clumps, and the filtrate was then centrifuged (250 g, 10 min). The
cell pellet was washed twice with serum-free RPMI 1640 and
resuspended in complete RPMI 1640. A 4-ml aliquot of cell
suspension of disaggregated tumor was placed on top of the
gradient formed by overlapping a cushion of 100% Ficoll-Paque
(Pharmacia Fine Chemicals, Piscataway, NJ) with an equal volume
of 75% Ficoll-Paque in RPMI 1640. Gradients (14 ml) were
centrifuged at 800 g for 30 min at room temperature. The distinct
band formed at the interface between 75% and 100% Ficoll-
Paque was collected and washed three times in fresh medium.
Flow cytometry
Flow cytometry was performed on a FACSCalibur (BD Biosciences)
with CellQuest Pro software using directly conjugated mAbs against
the following markers: CD3-FITC, CD4-PerCP, CD25-allophycocya-
nin, CCR6-PE with corresponding isotype-matched controls (either
BD Biosciences or eBioscience Systems). Foxp3 staining was conducted
using the mouse Regulatory T cell staining kit (eBioscience) and run
according to the manufacturer’sprotocol. To determine the percentage
of CCR6
+ Tregs and CCR6
2Tregs, lymphocytes were gated by
plotting forward vs side scatter followed by gating on CD4
+CD25
high T
cells, and these cells were then analyzed for Foxp3 expression and
CCR6 expression.
To determine the expression level of CD107a on CD8
+ T cells,
after staining of surface markers (CD8), cells were washed twice
with PBS. Antibodies to CD107a and corresponding isotype
controls were obtained from BD Biosciences. Cells were stained
with antibody against CD107a (1:100) at 25uC for 20 min and
washed before analysis.
Suppression assays
To test CCR6
+ Treg cells suppressive activity, 5610
4
CD4
+CD25
2 cells were treated with 2 mg/ml anti-CD3(e-
Bioscience) and anti-CD28 (eBioscience) for 12 hrs as effector
cells, then incubated with or without CCR6
+ Tregs at a ratios of
2:1 for 72 hrs in complete medium containing RPMI 1640 (Sigma,
St. Louis, MO) supplemented with 5% FCS.
[3H
]thymidine
(0.5 mCi/well) was added for the last 18 hours of culture.
Figure 2. In situ expansion of CCR6
+Tregs contributed to their prior accumulation in tumor mass. (A) The 4T1-bearing mice were treated
with 2 mg BrdU i.p. every other day up to a cumulative dose of 8 mg BrdU. Then TILs was collected and analyzed. The gating strategy was shown.
The proliferation and cell cycle of CCR6
+Tregs and CCR6
2Tregs were analyzed by FACS. (B) CCR6
+ Tregs and CCR6
2Tregs were purified by FACS from
TILs and labeled with CFSE respectivley. Then, 1610
6 CFSE-labeled cells were injected into tumor mass in 4T1-bearing mice. 10 days later, the
proliferation of CFSE labeled CCR6
+Tregs or CCR6
2Tregs was analyzed by FACS. (C). 4T1 bearing Balb/c mice were injected with or without 200 ug
vinblastine sulfate through tail vein as reported previously [15]. 15 hours later, CCR6
+Tregs were sorted by FACS from TILs and the proliferation were
analyzed by FACS and calculated. And the percentage of CCR6
+Tregs in PBMCs, DLNs and TILs also were analyzed by FACS and calculated (D). (E) The
percentage of CD4
+CD25
high Tregs in PBMCs, DLNs and TILs also were analyzed by FACS and calculated. One representative data of three
independent experiments was shown.* p,0.05.
doi:10.1371/journal.pone.0020282.g002
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T h e4 T 1b e a r i n gB a l b / cm i c ea n ds y n g e n e i cn u d em i c ew e r e
treated with 2 mg BrdU(5-bromo-2-deoxyuridine; Sigma) i.p. every
other day up to a cumulative dose of 8 mg BrdU as indicated. Eight
hours after the last BrdU injection, TILs recovered from the tumor
mass were analyzed by flow cytometry for their incorporation of BrdU.
In brief, TILs were stained with antibodies for cell surface markers and
fixed and permeabilized using Cytofix/Cytoperm and Perm/Wash
buffer (BD Biosciences) according to the manufacturer’s instructions.
Cells were incubated at 24uC for 30 min in 0.15 M NaCl, 4.2 mM
Figure 3. Tumor-resident DCs promoted the proliferation of CCR6
+Tregs in situ. (A) CD11c
+ DCs, macrophage or B cells were purified from
TILs by MACS. 2610
5 CCR6
+Tregs or CCR6
2Tregs were cultured with CD11c
+ DCs, macrophage or B cells from 4T1 bearing mice at a 1:2 ratio
respectively. 3 days later, the proliferation were determined by
[3H]thymidine incorporation assay. CD11c
+ DCs were purified from TILs and DLNs by
MACS. Proliferation of CCR6
+Tregs after culturing with DCs from TILs or DLNs at indicated ratio was determined (B). (C) Proliferation of CCR6
+Tregs
after culturing with DCs from TILs or DLNs at a ratio of 1:2 was determined at indicated time point as above described. (D) Proliferation of CCR6
+Tregs
after culturing with DCs at a ratio of 1:2 in the presence of anti-MHC class II antibody (10 ug/ml) for 3days. (E) The inhibitory activity of CCR6
+Tregs or
DC-expanded CCR6
+Tregs was determined. (F)4 610
5 CD11c
+ DCs were purified from TILs and intratumorally injected into 4T1 syngeniec bearing
mice (n=8). 10 days later, the proliferation of CCR6
+Tregs and CCR6
2Tregs were analyzed by BrdU incorporation assay respectively as above
described. One representative out of three independent experiments was shown. * p,0.05.
doi:10.1371/journal.pone.0020282.g003
Figure 4. DCs triggerred the proliferation of CCR6
+Treg in a TGF-b dependent manner. The 4T1-bearing mice were treated with 2 mg
BrdU i.p. every other day up to a cumulative dose of 8 mg BrdU. These mice also were simultaneously intratumorally injected 0.1-ml aliquots of Anti-
TGF-b antibody (50 ug) (&)( n=6) or rat IgG2a isotype control (%)( n=6) every other day. 8 hrs after last injection of BrdU, The TILs were collected.
The proliferation (A) and proportion (B) of CCR6
+Tregs in TILs were analyzed by FACS and calculated. (C) Proliferation of CCR6
+Tregs after culturing
with DCs at a ratio of 1:2 in the presence of anti-TGF-b or isotype control antibody (10 ug/ml) for 3 days. (D) CD11c
+ DCs were purified from TILs by
MACS. 1610
5 DCs was cultured and transfected with TGF-b RNAi or Scramble control. 72 hrs later, the supernatant concentration of TGF-b were
determined by ELSA assay. (E)1 610
5 CCR6
+ Tregs were cocultured with DCs transfected with TGF-b RNAi or scramble control at a ratio of 1:2. 72 hrs
later, the proliferation of CCR6
+Tregs was determined. * p,0.05.
doi:10.1371/journal.pone.0020282.g004
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(Invitrogen), followed by staining with aBrdU-FITC (eBioscience) for
30 min and were finally analyzed by FACS.
Design of artificial siRNAs and transfection
We designed the TGF-b targeting sequence (sense, 59-GAC-
CAUCGACAU- -GGAGCUG-39). The nonspecific control siRNA
duplexes were purchased from Dhamacon with the same GC content
as TGF-b siRNAs (52.4%, D001810-02). These siRNA gene double-
strands were ligated with pSilencer2.0 U6 RNAi Expression Vector
(Ambion). Then, the vector with TGF-b–siRNA or control siRNA
plasmids were transiently transfected into the CD11
+DC cells using
Lipofectamine-2000 (Invitrogen) according to the manufacturer’s
instruction.
Chemotaxis assay
Chemotaxis assays were performed using 24-well Transwell
chemotaxis plates (5-mm pore size; Corning Costar) as described
previously [15]. Cell culture supernatants from 4T1 tumor cell
lines or various concentrations of recombinant murine CCL17,
CCL20, or CCL22 (100 ng/mL; R&D Systems, Minneapolis,
MN) in RPMI 1640 medium were added to the lower chamber of
the Transwell plates. CCR6
+Tregs or CCR6
2Tregs (1610
5 cells)
were transferred into upper chambers. After 150 min at 37uC,
chemotaxis was quantified by detecting the numbers of cells that
migrated into the lower chamber. The chemotaxis index was
calculated by dividing the numbers of cells migrated in response to
test supernatants or recombinant human chemokines by the
numbers of cells migrated in response to medium alone.
To obtain culture supernatant, 4T1 cell lines (0.5610
6/ml) were
cultured for 48 hrs. The culture supernatants then were collected
and used in chemotaxis assays. For Ab-blocking assays, various
concentrations of neutralizing anti-CCL22 (500 ng/mL), anti-
CCL17(500 ng/mL), and anti-CCL20 (500 ng/mL) (R&D Sys-
tems) Abs were added to supernatants and incubated at 37uC for
30 min before performing chemotaxis assays.
Enzyme-linked immunosorbent assays
Tumor cell lines (0.5610
6/ml) were cultured for 48 hrs. The
culture supernatants were collected and performed using Quanti-
kine Immunoassay kits specific for murine CCL17, CCL22 and
CCL20, according to the manufacturer’s instructions (all from
R&D Systems).
Intracellular staining for IFN-c and Granzyme B
TILs were isolated from 4T1 bearing syngeneic nude mice
transferred with CD8
+T cells, CD8
+T cells plus CCR6
+Treg and
CD8
+T cells plus CCR6
2Treg respectively as indicated time point.
After staining of surface markers (CD8), cells were fixed and
permeabilized using Cytofix/Cytoperm and Perm/Wash buffer from
BD Biosciences according to the manufacturer’s instructions. Anti-
bodies to IFN-c or Granzyme B and corresponding isotype controls
were obtained from BD Biosciences. Cells were stained with antibody
against IFN-c (1:100) or antiboy against Granzyme B (1:100) at 25uC
for 20 min and washed twice in Perm/Wash before analysis.
CFSE labeling
Cells were purified from 4T1 bearing mice by FACS sorting
and labeled with 5-carboxy-fluorescein diacetate succinimidyl ester
(CFSE; Molecular Probes, Leiden, The Netherlands) as previously
described [3]. 2610
6 CFSE-labeled cells were intratumorally
injected into 4T1 bearing syngeneic mice. 10 days later, single-cell
suspensions of tumor infiltrating lymphocytes were prepared and
the proliferation of cells were analyzed by FACS.
Statistical analyses
Statistical analyses of the data were performed with the aid of
analysis programs in SPSS12.0 software. Statistical evaluation was
performed using one way analysis of variance (ANOVA; p,0.05) or
t test using the program PRISM 4.0 (GraphPad Software Inc., San
Diego, CA, USA).
Supporting Information
Figure S1 The migration of CCR6
+ Treg cells and
CCR6
2Treg cells in response to CCL17/CCL22 and
CCL20. The migration of CCR6
+Tregs and CCR6
2Tregs in
response to CCL17/CCL22 (100 ng/ml) or CCL20 (100 ng/ml)
were perfomed by transwell migration assays respectively as
described in Material and Methods. One representative data of three
independent experiments was shown. *p,0.05.
(DOC)
Figure S2 The supernatant concentration of CCL17,
CCL20 and CCL22. 4T1 tumor cell lines (5610
5/ml) were
cultured for 48 hrs. The culture supernatants were collected and
the concentration of CCL17, CCL20 and CCL22 were deter-
mined by ELISA assay and calculated. One representative data of
three independent experiments was shown.
(DOC)
Figure S3 CCR6
+ Treg cells and CCR6
2Treg cells migrate
in response to 4T1 supernatants. 4T1 tumor cell lines (5610
5/
ml) were cultured for 48 hrs. The culture supernatants were collected.
The migration of CCR6
+Tregs or CCR6
2Tregs in response to
supernatants were perfomed by transwell migration assays as described
in Material and Methods. After preincubation for 30 minutes at 4uCw i t h
anti-CCL17, anti-CCL20 and anti-CCL22 mAbs (500 ng/mL),
CCR6
+Tregs and CCR6
2 Tregs migration were also tested by
transwell migration assays respectively. One representative data of
three independent experiments was shown. *p,0.05.
(DOC)
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Figure 5. The proliferation of CCR6
+Tregs in situ was crucial for their suppressive function in vivo. Balb/c mice were immunized with
inactivated 4T1 tumor cells 3 times, with 1-week-interval. Then CD8
+ T cells were sorted from splenocytes and re-stimulated with inactivated 4T1
tumor cells for 24 h in vitro. CCR6
+Tregs and CCR6
2Tregs were purified from TILs and treated with or with vinblastine (50 ng/ml) for 12 hrs. Then
CD8
+T cells were transferred with CCR6
+Treg or CCR6
2Tregs pretreated with or without vinblastine at a ratio of 2:1 into syngeneic 4T1-bearing nude
mice (n=8). 10 days later, the proportion of CCR6
+Tregs or CCR6
2Tregs in TILs of 4T1 bearing nude mice was analyzed by FACS and calculated (A).
CD8
+T cells in tumor mass also were obtained. The percentage of IFN-c secreting CD8
+ T cells (B), as well as the expression of CD107a and Granzyme
B on CD8
+T cells (C), were analyzed by FACS. Symbols were representative of three independent experiments. Medians were indicated. (D) And the
proliferation of CD8
+T cells were also obtained by BrdU incorporation assay and calculated. (E) 21 day later, the tumor size in each group also was
obtained.* p,0.05.
doi:10.1371/journal.pone.0020282.g005
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